FDA sharps device requirements
This article was originally published in The Gray Sheet
Executive Summary
FDA establishes interim policy that scales back clinical data requirements outlined in its draft guidance on sharps devices with injury prevention features. Under the interim policy, which will be in effect until FDA finalizes revisions to the draft, "a modicum" of in-use data will be required to demonstrate safety and effectiveness of the devices, FDAers say. The amount and type of data will depend upon the device's intended use. The clinical data provisions in the draft came under criticism at a May meeting of FDA's General Hospital and Restorative Devices Advisory Panel ("The Gray Sheet" May 16, I&W-1)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.